Tables
- TABLE 1
Functional status and right heart catheterisation at baseline, as well as 1 and 2 years after discontinuation of interferon-β and initiation of pulmonary arterial hypertension-specific therapy
Baseline 1 year 2 years 6MWT m 513 502 NYHA-FC III II II RAP mmHg 5 6 3 PAP syst/diast/mean mmHg 74/42/53 49/21/30 41/20/27 PAWP mmHg 10 7 6 CO L·min−1 3.3 6.5 6.3 CI L·min−1·m−2 1.9 3.8 3.7 PVR Wood units 13 3.5 3.3 Vasoreactivity testing during the first right heart catheterisation with intravenous epoprostenol up to 12 ng·kg−1·min−1 was negative. 6MWT: 6-min walking test; NYHA-FC: New York Heart Association functional class; RAP: right atrial pressure; PAP: pulmonary artery pressure; syst: systolic; diast: diastolic; PAWP: pulmonary artery wedge pressure; CO: cardiac output; CI: cardiac index; PVR: pulmonary vascular resistance.
Vol 6 Issue 1
Table of Contents
Is pulmonary arterial hypertension associated with interferon-β therapy for multiple sclerosis reversible? A case study to explore the complexity
